Myles Wolf mostly deals with Internal medicine, Endocrinology, Kidney disease, Fibroblast growth factor 23 and Vitamin D and neurology. His study focuses on the intersection of Internal medicine and fields such as Gastroenterology with connections in the field of Quartile. His Endocrinology research includes themes of Nephrology, Parathyroid hormone, Pathogenesis and Preeclampsia.
The various areas that Myles Wolf examines in his Kidney disease study include Etelcalcetide, Dialysis, End stage renal disease and Renal function. His work carried out in the field of Fibroblast growth factor 23 brings together such families of science as Calcitriol, Phosphorus metabolism, Inflammation, Phosphate and Thoracic aorta. His work deals with themes such as Genetics, National Health and Nutrition Examination Survey, Physiology and Disease, which intersect with Vitamin D and neurology.
Internal medicine, Endocrinology, Kidney disease, Fibroblast growth factor 23 and Renal function are his primary areas of study. Myles Wolf interconnects Gastroenterology and Cardiology in the investigation of issues within Internal medicine. Myles Wolf usually deals with Gastroenterology and limits it to topics linked to Hazard ratio and Proportional hazards model.
Myles Wolf works mostly in the field of Endocrinology, limiting it down to topics relating to Secondary hyperparathyroidism and, in certain cases, Hyperparathyroidism. As a member of one scientific family, Myles Wolf mostly works in the field of Kidney disease, focusing on Cohort and, on occasion, Heart failure. In his work, Urinary system is strongly intertwined with Excretion, which is a subfield of Fibroblast growth factor 23.
His primary areas of study are Internal medicine, Kidney disease, Fibroblast growth factor 23, Renal function and Gastroenterology. His Internal medicine study combines topics in areas such as Endocrinology and Cardiology. Myles Wolf studied Endocrinology and Calcium that intersect with Calciphylaxis.
His research integrates issues of Biomarker, Cohort study, Cohort and Receiver operating characteristic in his study of Kidney disease. His Fibroblast growth factor 23 study integrates concerns from other disciplines, such as Interquartile range, Secondary hyperparathyroidism, Anemia and Bone remodeling. His Gastroenterology study combines topics from a wide range of disciplines, such as Adverse effect, Phosphate, Randomized controlled trial and Iron-deficiency anemia.
His primary scientific interests are in Internal medicine, Kidney disease, Fibroblast growth factor 23, Renal function and Gastroenterology. His Internal medicine research incorporates elements of Diabetes mellitus and Cardiology. Myles Wolf interconnects Disease, Cohort and Bioinformatics in the investigation of issues within Kidney disease.
His Fibroblast growth factor 23 research includes themes of Phosphate binder, Anemia and Hemodialysis. His work carried out in the field of Gastroenterology brings together such families of science as Iron-deficiency anemia, Tolerability, Adverse effect, Bicarbonate and Phosphate. Hyperphosphatemia is a primary field of his research addressed under Endocrinology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Vitamin D Deficiency and Risk of Cardiovascular Disease
Thomas J. Wang;Michael J. Pencina;Sarah L. Booth;Paul F. Jacques.
FGF23 induces left ventricular hypertrophy
Christian Faul;Ansel P. Amaral;Behzad Oskouei;Ming Chang Hu.
Journal of Clinical Investigation (2011)
Common genetic determinants of vitamin D insufficiency: a genome-wide association study
Thomas J. Wang;Feng Zhang;J. Brent Richards;Bryan Kestenbaum.
The Lancet (2010)
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
Orlando M. Gutiérrez;Michael Mannstadt;Tamara Isakova;Jose Alejandro Rauh-Hain.
The New England Journal of Medicine (2008)
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey.
David Martins;Myles Wolf;Deyu Pan;Ashraf Zadshir.
JAMA Internal Medicine (2007)
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Tamara Isakova;Patricia Wahl;Gabriela S. Vargas;Orlando M. Gutiérrez.
Kidney International (2011)
Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Ming Teng;Myles Wolf;Edmund Lowrie;Norma Ofsthun.
The New England Journal of Medicine (2003)
Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease
Tamara Isakova;Huiliang Xie;Wei Yang;Dawei Xie.
Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease
Orlando Gutierrez;Tamara Isakova;Eugene Rhee;Anand Shah.
Journal of The American Society of Nephrology (2005)
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Ming Teng;Myles Wolf;M. Norma Ofsthun;J. Michael Lazarus.
Journal of The American Society of Nephrology (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: